Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02382380 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Gadoterate in Patients With Renal Dysfunction
A Phase 4 study, sponsored by Loyola University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT02382380: Clinical Trial Phase 4 study, sponsored by Loyola University.
NCT02382380 is a Phase 4 study that was terminated before completion, run by Loyola University. The registered enrollment target is 46 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02382380, a Phase 4 study, was terminated before completion, sponsored by Loyola University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study is for individuals with decreased kidney function whose doctor has ordered Magnetic Resonance Imaging (MRI). Because kidney function is decreased, these patients usually do not receive the intravenous contrast material that can improve the accuracy of the MRI findings. The purpose of this study is to evaluate the safety and benefit of using a contrast material called Gadoterate in patients with decreased kidney function.
Primary Outcome
Change in GFR from 0 to 72 hours
Interventions
- DRUG Gadoterate
- OTHER No Gadoterate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2014-11-05 |
| Est. Completion | 2024-03-20 |
| Phase | Phase 4 |
Why NCT02382380 stopped before completion
NCT02382380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Gadoterate is the first listed.
NCT02382380 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02382380 about?
NCT02382380 is a clinical study titled "Evaluation of Gadoterate in Patients With Renal Dysfunction". This study is for individuals with decreased kidney function whose doctor has ordered Magnetic Resonance Imaging (MRI). Because kidney function is decreased, these patients usually do not receive the intravenous contrast material that can improve the accuracy of the MRI findings. The purpose of this...
What is the current status of trial NCT02382380?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2014-11-05. Estimated completion is 2024-03-20.
What interventions are being tested in trial NCT02382380?
The interventions under investigation include: Gadoterate (DRUG), No Gadoterate (OTHER).
Who is sponsoring clinical trial NCT02382380?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02382380's enrollment target sits among peer trials
46 1348th of 2000 higher than 647 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI